Adage Capital Management Reiterates Stake in CARDIOME PHARMA CORP (CRME)
In its latest filing, Adage Capital Management, managed by Phill Gross and Robert Atchinson, has reported ownership of 1.33 million shares of CARDIOME PHARMA CORP (NASDAQ:CRME). The stake amasses 8.9% of the company’s common shares, and is unchanged from the end of the third quarter of 2013.
CARDIOME PHARMA CORP (NASDAQ:CRME) is a specialty pharmaceutical company dedicated to the development and commercialization of cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease.
Jim Simons’s Renaissance Technologies owned 210,113 shares of CARDIOME PHARMA CORP (NASDAQ:CRME) at the end of third quarter of 2013. Ken Griffin’s Citadel Investment Group held 10,782 shares of the company by the end of third quarter.
In late November 2013, Fortress Investment Group, managed by Michael Novogratz, reported adding CARDIOME PHARMA CORP (NASDAQ:CRME) to its equity portfolio, in a new filing with the Securities and Exchange Commission. Fortress disclosed a passive stake, which amasses 2.5 million shares, with an aggregate value of $15.4 million at the current share price of the company.
The largest stake in Adage Capital equity portfolio is represented by Apple Inc. (NASDAQ:AAPL), in which Adage Capital disclosed 1.38 million shares worth about $657.41 million.
Adage Capital was founded by Phil Gross and Robert Atchinson in 2001. Gross was initially a healthcare and retail analyst at the Harvard Management Company (HMC). Later, he became a partner at the company, where he spent 18 years.
In December, Adage Capital reported raising its exposure to Heartware International Inc. (NASDAQ:HTWR) to 836,190 shares, from 688,952 shares held at the end of September, as revealed in the fund's latest 13G. Adage Capital Management disclosed ownership of 5.07% of the company's common stock.